Find our press release as a PDF here in addition to being found below. Emergency access granted to investigational therapyObjective to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation Discussions with international regulators, KOLs and clinical centres of excellence are ongoing to progress namilumab OXFORD, England, April 06, 2020 – Izana Bioscience…Read More
Oxford, UK – 13 August 2018: Izana Bioscience, a biopharmaceutical company focused on translational medicine, today announced the initiation of a phase II proof-of-concept clinical study of namilumab in ankylosing spondylitis, a debilitating arthritic disease of the spine that affects millions of people worldwide. The randomized, double-blind, placebo-controlled NAMASTE study (Namilumab in Ankylosing Spondylitis Therapy) will enrol over 40…Read More
Find our press release as a PDF here in addition to being found below. Namilumab exclusive worldwide licence granted by Takeda Awarded £1.35 million grant by Innovate UK to support phase II proof-of-concept study Highly experienced management team; co-founded by serial entrepreneur Bryan Morton Oxford, UK – 14 December 2017: Izana Bioscience (“Izana” or “the Company”) launches…Read More
Send us an email using the form and one of the team will be in touch with you soon.